New York, NY & Houston, TX — PranaQ has entered a strategic partnership with Artella Solutions Inc. (“ARTELLA”), a leader in SaaS-driven cardiac monitoring and diagnostic intelligence.
This collaboration brings PranaQ’s FDA-cleared Home Sleep Test (HST) system into ARTELLA’s Active State Monitoring platform, enabling cardiology practices and hospital systems to seamlessly order, manage, and review sleep studies alongside cardiac diagnostics. ARTELLA will launch the integrated offering under its CARDIOSLEEP program.
With Obstructive Sleep Apnea (OSA) and Atrial Fibrillation (AFib) deeply interconnected clinically, the partnership creates a unified pathway for clinicians to diagnose and manage both conditions with a single operational workflow.
Simplifying Diagnostics Across Two Interconnected Conditions
Through the integration, ARTELLA customers gain access to PranaQ’s complete home sleep testing ecosystem — including test logistics, automated scoring, and physician-ready reports — within their existing workflow.
Key benefits for clinical teams include:
- Turn-key sleep diagnostic workflow embedded in the Active State platform
- Automated logistics, scoring, and reporting
- A single operational experience for both cardiac and sleep diagnostics
“We built ARTELLA to simplify diagnostic workflows for clinicians. Integrating sleep testing into the platform gives practices a streamlined way to manage two highly correlated conditions with one partner,” said Sepand Moshiri, CEO of Artella Solutions.
Why Cardiology Practices Need a Sleep Testing Pathway
The clinical overlap between OSA and AFib is clear and compelling:
- 50–80% of AFib patients have OSA
- Untreated OSA increases AFib recurrence 2–4x after ablation
- CPAP therapy for diagnosed OSA can reduce AFib recurrence by up to 42%
- ~30 million U.S. adults have OSA, but 80% remain undiagnosed
“In many patients, AFib is secondary to untreated obstructive sleep apnea,” said Joseph Hashim, EVP of Commercialization & Strategy at Artella Solutions. “By diagnosing and treating OSA, clinicians can improve AFib management and, in some cases, eliminate the arrhythmia entirely.”
Expanding PranaQ’s Reach Across Cardiology
By partnering with ARTELLA, PranaQ brings accessible home sleep testing into cardiology settings where OSA is common but often underdiagnosed.
“PranaQ is focused on improving access to sleep diagnostics. Partnering with ARTELLA brings our home sleep testing ecosystem into cardiology settings that see OSA every day but don’t always have an efficient pathway to diagnose it,” said Jerry Chen, CEO of PranaQ.
This collaboration extends PranaQ’s reach across ARTELLA’s national provider network while enabling ARTELLA to expand beyond cardiac monitoring and into Sleep Medicine.
About PranaQ
PranaQ is a digital health company making sleep diagnostics simpler, faster, and more accessible. Its FDA-cleared Home Sleep Test system enables clinicians to diagnose and manage sleep apnea with high accuracy, streamlined workflows, and rapid results.
For more information, please visit pranaq.com.
LinkedIn: linkedin.com/company/pranaq/.
About Artella Solutions
Artella Solutions Inc. provides remote cardiac monitoring and diagnostic software solutions designed to improve data review efficiency and patient care. ARTELLA combines patch-based monitoring, artificial intelligence, and unified reporting tools to support physicians in identifying cardiac rhythm abnormalities.
For more information, please visit artellainc.com.
LinkedIn: linkedin.com/company/artella-solutions